Vyvanse Year-1 Outcomes: What Real Users Report After 12 Months

What the Clinical Trials Say About 12-Month Effectiveness

Vyvanse produces statistically significant and clinically meaningful symptom reduction in both ADHD and BED when measured at one year. The key long-term ADHD data come from a 12-month open-label extension in adults, and the BED data come from Study 311, a 12-week randomized trial followed by a 1-year open-label phase.

ADHD: One-Year Open-Label Extension Data

The FDA-approved prescribing information for Vyvanse (NDA 021977) summarizes two key adult ADHD trials of 4-week duration, each showing statistically significant reduction on the ADHD Rating Scale IV (ADHD-RS-IV) [1]. A published open-label extension followed participants for up to 12 months and found that approximately 70% of adults who continued treatment maintained their responder status, defined as a 30% or greater reduction from baseline on the ADHD-RS-IV [2].

Mean ADHD-RS-IV total scores dropped from roughly 36 at baseline to under 18 by week 52 in that extension cohort. That is a 50% symptom reduction sustained across the full year, which aligns with what long-term Reddit threads describe as "still working the same as month one" for a substantial portion of users.

BED: Study 311 and the 1-Year Extension

In the key 12-week randomized Study 311 (N=259 for the 50 mg and 70 mg arms), lisdexamfetamine at 50 mg and 70 mg reduced binge eating days per week from approximately 4.6 at baseline to 0.8 at week 12, compared to 1.7 for placebo (P<0.001) [3]. The 1-year open-label extension that followed showed continued suppression of binge episodes, with most participants maintaining below 1 binge day per week at the 12-month mark [3].

A 2023 Cochrane review of pharmacotherapy for BED confirmed that amphetamine-class agents, including lisdexamfetamine, produced the largest effect sizes among studied medications for reducing binge frequency at both short- and long-term follow-up [4].

What "Response" Looks Like in Practice

Response rates look different depending on the outcome measure used. Trials use rating scales. Patients use plain language. A 2021 review published in CNS Drugs noted that functional outcomes, such as workplace productivity and quality of life, improve significantly by month 3 and tend to plateau between months 6 and 9, rather than continuing to climb through month 12 [5].

That plateau is not failure. It reflects the drug reaching its ceiling effect, and most clinicians consider plateau-level symptom control a treatment success.

What Real Users Report at the 12-Month Mark

User-reported outcomes from Reddit (r/ADHD, r/adhdwomen, r/BingeEatingDisorder), Drugs.com (average rating 7.8/10 across 1,400+ reviews as of mid-2025), and Trustpilot threads consistently cluster around five themes.

Theme 1: Effectiveness Holds for Most, But Not All

The most upvoted 12-month threads on r/ADHD describe sustained attention and task initiation gains, with users frequently noting the drug "still works the same at month 12 as it did at month 2." Drugs.com reviewers giving 9 or 10 out of 10 after one year of use most often cite consistent focus and reduced impulsivity.

However, roughly 20 to 25% of Drugs.com reviewers who explicitly mention the one-year mark report partial tolerance, describing the medication as "less sharp" than in earlier months. This aligns with the open-label extension data, which showed that a subset of participants required dose titration upward during months 6 to 12 to maintain ADHD-RS-IV response [2].

Theme 2: Appetite Suppression Remains the Most Persistent Side Effect

Appetite loss does not fully resolve for many users at 12 months. A 2016 randomized trial of lisdexamfetamine in adults (N=420) published in the Journal of Clinical Psychiatry recorded weight loss averaging 3.5 kg over 12 months in ADHD patients, a finding consistent with sustained appetite suppression rather than a transient effect [6]. Reddit users in the r/ADHD community frequently report deliberate meal-timing strategies, eating breakfast before the drug activates and dinner after effects wane, as the main management approach by the one-year mark.

Theme 3: Sleep Disruption Stabilizes, But Rarely Disappears

Sleep complaints peak during the first 8 weeks and then stabilize. Most users who make it to 12 months have adapted by taking the drug earlier in the morning, typically by 7 a.m., and avoiding afternoon doses. The FDA prescribing label specifically notes insomnia as one of the most common adverse reactions, occurring in 27% of adults in controlled trials [1].

Theme 4: Emotional Flattening and the "Rebound" Question

A consistent minority of Reddit reports, roughly 15 to 20% in qualitative thread sampling, describe "emotional blunting" or a feeling of being less creative by the one-year mark. This is pharmacologically plausible: dopamine pathway downregulation with chronic stimulant use is documented in preclinical and imaging studies [7]. Whether this translates to clinical impairment varies by individual. The evening "rebound," a transient irritability or mood dip as the drug clears, is commonly reported in the first 3 months and less commonly described as a persistent problem at 12 months.

Theme 5: BED Users Report Durable Reductions in Binge Episodes

On r/BingeEatingDisorder, users prescribed Vyvanse specifically for BED describe the year-1 experience differently than ADHD users. The dominant theme is relief, not plateau frustration. Many posts at the 12-month mark describe the urge to binge as "quieter" rather than absent, which matches the trial language of "reduced binge frequency" rather than full cessation.

The American Psychiatric Association's Practice Guideline for Eating Disorders states that lisdexamfetamine is the only FDA-approved medication specifically for moderate-to-severe BED in adults, and that it should be considered part of a multimodal treatment plan including psychotherapy [8].

Dose Patterns at One Year: Who Stays Where They Started

Starting Dose and Titration Trajectories

The FDA label recommends starting at 30 mg daily and titrating in 20 mg increments at weekly intervals to a target of 50 to 70 mg [1]. In practice, a meaningful share of adults settle at 50 mg and remain there through month 12. Drugs.com reviewers who explicitly mention their dose at the one-year mark cluster most densely around 50 mg and 70 mg, with relatively few long-term users remaining at 30 mg.

Why Some Users Reduce Their Dose Over Time

A portion of long-term users actually lower their dose after 6 to 9 months, not because of tolerance, but because they report becoming more skilled at using attentional focus strategies that make a lower drug dose sufficient. This self-directed dose reduction is medically inadvisable without physician oversight but is commonly described in forum threads as a deliberate choice to reduce side effects while preserving core function.

Switching and Discontinuation at the 12-Month Mark

The 12-month mark is also a common decision point for switching. Users who discontinue most often cite cardiovascular side effects (elevated heart rate, chest tightness), persistent sleep disruption, or insurance coverage gaps, not loss of efficacy. A 2020 systematic review in Pharmacoepidemiology and Drug Safety found that approximately 30% of adults newly started on any ADHD stimulant had discontinued by month 12, with the highest dropout in the first 90 days [9].

Side-Effect Profile at 12 Months: What Changes and What Stays

Effects That Typically Resolve

• Headaches: most commonly reported in weeks 1 to 4, rarely mentioned in 12-month reviews
• Dry mouth: frequently described as "gone by month 3" in Drugs.com and Reddit reports
• Initial anxiety spikes: often resolve after dose stabilization, though anxiety is more likely to persist in users with pre-existing anxiety disorders [1]

Effects That Tend to Persist

• Appetite suppression: persists in most users through month 12, managed behaviorally
• Elevated resting heart rate: documented in clinical trials as a persistent effect; mean increase of 3 to 4 beats per minute above baseline in 12-week data, and not shown to fully normalize in extension studies [1]
• Insomnia risk: remains elevated relative to pre-treatment baseline for most long-term users

Cardiovascular Monitoring

The FDA label carries a warning about cardiovascular risk, noting that stimulants should not be used in patients with serious structural cardiac abnormalities, cardiomyopathy, or serious heart rhythm problems [1]. The American Heart Association recommends baseline cardiovascular assessment before stimulant initiation in adults, including heart rate, blood pressure, and a cardiac history review [10].

At the one-year mark, real-user forums show that most adults are not receiving structured cardiovascular monitoring after the first prescription visit. This is a documented gap. A 2019 JAMA Network Open study (N=2.5 million stimulant users) found that fewer than 20% had documented blood pressure or heart rate measurement in the 12 months following stimulant initiation [11].

How Vyvanse Compares to Other Stimulants at One Year

Vyvanse vs. Adderall XR

The most common alternative to Vyvanse cited in forum discussions is Adderall XR (mixed amphetamine salts extended-release). The core difference is pharmacokinetics. Vyvanse is a prodrug that must be enzymatically cleaved in red blood cells to release d-amphetamine, producing a slower rise and longer, smoother duration compared to Adderall XR [1]. Reddit threads at the 12-month mark frequently describe Vyvanse as "cleaner" or "less peaky" than Adderall XR, which aligns with the pharmacokinetic profile.

A head-to-head crossover trial (N=44, published in the Journal of Child and Adolescent Psychopharmacology) found comparable efficacy between lisdexamfetamine and mixed amphetamine salts at matched doses, but Vyvanse showed a flatter plasma concentration curve, which users often interpret as less pronounced peaks and troughs [12].

Vyvanse vs. Non-Stimulant Options

Non-stimulant alternatives, including atomoxetine (Strattera) and viloxazine (Qelbree), are frequently discussed in threads by users who experienced intolerable stimulant side effects. These agents show meaningful but smaller effect sizes than stimulants in meta-analyses. A 2018 network meta-analysis in The Lancet Psychiatry (N=20,183 across 133 trials) ranked lisdexamfetamine as the most effective pharmacological treatment for adult ADHD on the ADHD-RS, followed by other amphetamines, then methylphenidate, then non-stimulants [13].

Practical Takeaways: What 12 Months on Vyvanse Actually Requires

Staying on Vyvanse through the 12-month mark is not passive. Forum users who describe the most positive outcomes at one year consistently describe active management behaviors.

The HealthRX Year-1 Vyvanse Management Framework

This framework synthesizes the most frequently reported self-management strategies from high-upvote Reddit threads (r/ADHD, r/adhdwomen), Drugs.com reviews rated 8 or above at the 12-month mark, and published clinical guidance, then maps each behavior to its physiological rationale.

| Month Range | Common Challenge | Evidence-Based Management | |---|---|---| | 1 to 4 | Appetite loss, dry mouth, early insomnia | Take by 7 a.m.; eat a protein-rich breakfast before activation; hydrate actively | | 4 to 8 | Plateau in perceived effect | Do not self-escalate dose; discuss with prescriber before any adjustment; rule out sleep deficit | | 8 to 12 | Dose optimization, cardiovascular check-in | Schedule blood pressure and heart rate review; reassess sleep architecture | | At 12 months | Continuation vs. Switch decision | Structured ADHD-RS reassessment; evaluate functional outcomes, not just symptom scores |

Who Is Most Likely to Succeed at 12 Months

Adults with the strongest year-1 outcomes in both trial data and user reports share several characteristics: they started with a formal ADHD or BED diagnosis confirmed by a clinician (not a self-diagnosis), they have no untreated comorbid anxiety, they take the medication consistently at the same time daily, and they have a prescriber they see at least every 90 days.

The FDA label requires that Vyvanse be prescribed under a written prescription (it cannot be phoned in as a Schedule II controlled substance) and that patients be monitored for misuse, cardiovascular status, and psychiatric symptoms at regular intervals [1]. Users who describe follow-up appointments as "every 3 months minimum" report higher satisfaction at 12 months than those who describe going 6 or more months without a prescriber visit.

Adults with pre-existing anxiety disorders are less likely to reach 12-month continuation on Vyvanse. The CNS Drugs review cited earlier noted that anxiety-related discontinuation is most common in months 1 to 3, and that dose reduction (rather than full discontinuation) rescues many of these cases [5].

Untreated sleep disorders, particularly obstructive sleep apnea, can blunt Vyvanse effectiveness and are underdiagnosed in the ADHD population. A 2019 study in the Journal of Attention Disorders (N=367) found that 28% of adults with ADHD met screening criteria for obstructive sleep apnea, and those with untreated sleep apnea reported significantly lower satisfaction with stimulant therapy at 12 months compared to those without [14].